Wegovy costs $1.3m to prevent one heart attack, stroke, or cardiovascular death
Anti-obesity drug rush: Industry 'testing' nearly 190 candidates (es)
Weight loss injections could prevent 300,000 heart failures in the US by 2030, forecasts Airfinity
Airfinity forecasts the severely obese population with metabolic syndrome in the US to grow 50% by 2030 from 26 million to 39.1 million people.
View All →
In a dynamic environment, Airfinity enabled us to remain on track with daily developments to enable more accurate decision-making. Airfinity combines nimbleness of real time data and their group of scientists that can analyse, model and provide strategic analysis for critical decision making.”
Iskra Reic, Executive Vice-President
Astrazeneca
“Airfinity is a true partner in pushing the absolutely critical work we do to advance vaccines into the clinical space. Their team provides exceptional collaboration and intelligent data analytics that support our organisation in business and scientific decision making in a challenging, rapidly evolving emerging disease field.”
GeoVax
“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are important for evidence–based policy making.”
Director General ,
IFPMA